Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 08, 2020 07:30 ET | Source: Axovant Sciences Ltd.

Axovant Completes Enrollment of Low-Dose Cohort in Phase 1/2 Study of AXO-AAV-GM1 and Expands Study to Include Type I (Infantile Onset) Patients with GM1 Gangliosidosis

- Six-month data from low-dose cohort expected in Q4 2020- IND amended to include Type I (infantile onset) patients and to evaluate a higher dose- Expect to initiate high-dose cohort in 2H 2020 ...
May 28, 2020 08:00 ET | Source: Axovant Sciences Ltd.

Axovant Gene Therapies to Present at the 2020 Jefferies Global Virtual Healthcare Conference

NEW YORK and BASEL, Switzerland, May 28, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological...
May 07, 2020 08:00 ET | Source: Axovant Sciences Ltd.

Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy

NEW YORK and BASEL, Switzerland, May 07, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases,...
April 24, 2020 07:30 ET | Source: Axovant Sciences Ltd.

Axovant Announces Full Prepayment of Outstanding Loan from Hercules Capital

NEW YORK and BASEL, Switzerland, April 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. a clinical-stage company developing innovative gene therapies for neurological diseases, today...
April 15, 2020 08:00 ET | Source: Axovant Sciences Ltd.

Axovant Announces Partnership with Invitae to Increase Access to Genetic Testing and Accelerate Diagnoses of GM1 and GM2 Gangliosidosis

Partnership to reduce barriers to genetic diagnosis through sponsored testing for lysosomal storage diseases Initiative supports identification of patients with GM1 and GM2 gangliosidosis who are...
April 08, 2020 08:00 ET | Source: Axovant Sciences Ltd.

Axovant Provides Business and Operations Update During the COVID-19 Pandemic

Completed dosing of all patients in second cohort of AXO-Lenti-PD dose escalation studyAt present, Company remains on track to achieve key 2020 milestones NEW YORK and BASEL, Switzerland, April 08,...
March 31, 2020 08:00 ET | Source: Axovant Sciences Ltd.

Axovant to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

NEW YORK and BASEL, Switzerland, March 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological...
February 24, 2020 16:01 ET | Source: Axovant Sciences Ltd.

Axovant Gene Therapies Announces Closing of $74.7 Million Public Offering of Common Shares and Prefunded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK and BASEL, Switzerland, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the closing of its previously announced underwritten public...
February 19, 2020 22:11 ET | Source: Axovant Sciences Ltd.

Axovant Gene Therapies Announces Pricing of $65 Million Public Offering

NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the pricing of its underwritten public offering of...
February 19, 2020 16:02 ET | Source: Axovant Sciences Ltd.

Axovant Gene Therapies Announces Commencement of Public Offering

NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its...